We pinpointed critical residues responsible for the Gal-1/H-Ras(G12V) interaction and showed that LLS30, a Gal-1 inhibitor, targets the Ras-binding site on Gal-1, blocking the interaction and inhibiting tumor growth. The gene discussed is LGALS1; the disease is neoplasm.